Travere Therapeutics - TVTX Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Travere Therapeutics in the last twelve months. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TVTX shares.
View TVTX analyst ratings or view top-rated stocks.

7 analysts have issued 12-month price targets for Travere Therapeutics' shares. Their TVTX share price forecasts range from $17.00 to $42.00. On average, they anticipate the company's share price to reach $32.22 in the next twelve months. This suggests a possible upside of 47.1% from the stock's current price.
View analysts price targets for TVTX or view top-rated stocks among Wall Street analysts.

Travere Therapeutics' stock was trading at $21.03 at the beginning of the year. Since then, TVTX shares have increased by 4.2% and is now trading at $21.91.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our TVTX earnings forecast.

Travere Therapeutics, Inc. (NASDAQ:TVTX) announced its earnings results on Thursday, October, 28th. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.13. The company earned $68.20 million during the quarter, compared to analyst estimates of $60.93 million. Travere Therapeutics had a negative trailing twelve-month return on equity of 137.68% and a negative net margin of 123.82%. The company's revenue was up 33.5% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.44) EPS.

Travere Therapeutics updated its FY 2022 earnings guidance on Monday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $212.00 million-$212.00 million, compared to the consensus revenue estimate of $212.08 million.

Travere Therapeutics trades on the NASDAQ under the ticker symbol "TVTX."

Travere Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (1.35%), National Bank of Canada FI (0.18%), Oak Ridge Investments LLC (0.13%), Rice Hall James & Associates LLC (0.12%), Hennion & Walsh Asset Management Inc. (0.12%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Christopher R Cline, Elizabeth E Reed, Eric M Dube, Jula Inrig, Laura Clague, Noah L Rosenberg, Noah L Rosenberg, Peter Heerma, Sandra Calvin, Steve Aselage and William E Rote.
View institutional ownership trends.

Shares of TVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TVTX stock can currently be purchased for approximately $21.91.

Travere Therapeutics (NASDAQ:TVTX) has a market capitalization of $1.41 billion and generates $227.49 million in revenue each year. The company earns $-180,090,000.00 in net income (profit) each year or ($4.18) on an earnings per share basis.

The company employs 310 workers across the globe.

Travere Therapeutics' mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The official website for the company is www.retrophin.com. The company can be reached via phone at (888) 969-7879, via email at ir@retrophin.com, or via fax at 302-645-1280.